Cargando…

p53 Antibodies as a Diagnostic Marker for Cancer: A Meta-Analysis

Importance: The protein p53 is an unequivocal tumor suppressor that is altered in half of all cancers. The immune system produces systemic p53 autoantibodies (p53 Abs) in many cancer patients. Objective: This systemic review and meta-analysis focuses on the prognostic value of p53 Abs expressed in t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sobhani, Navid, Roviello, Giandomenico, D’Angelo, Alberto, Roudi, Raheleh, Neeli, Praveen Kumar, Generali, Daniele
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8541220/ https://www.ncbi.nlm.nih.gov/pubmed/34684792 http://dx.doi.org/10.3390/molecules26206215

Ejemplares similares

PAK6-Associated Support Vector Machine Classifier: A New Way to Evaluate Response and Survival of Gastric Cancer Treated by 5-FU/Oxaliplatin Chemotherapy
por: Sobhani, Navid, et al.
Publicado: (2017)

The combination of bevacizumab with chemotherapy is more beneficial in the metastatic setting rather than in the adjuvant setting for the treatment of HER2-negative breast cancer—a commentary on the E5103 randomized phase III clinical study
por: Roviello, Giandomenico, et al.
Publicado: (2019)

AR-V7 in Metastatic Prostate Cancer: A Strategy beyond Redemption
por: Sobhani, Navid, et al.
Publicado: (2021)

Predictive and Prognostic Value of Non-Coding RNA in Breast Cancer
por: Sobhani, Navid, et al.
Publicado: (2022)

Novel Agents in Heavily Pretreated Metastatic Gastric Cancer: More Shadows Than Lights
por: Roviello, Giandomenico, et al.
Publicado: (2019)

Mutant p53 as an Antigen in Cancer Immunotherapy
por: Sobhani, Navid, et al.
Publicado: (2020)

Current Status of Fibroblast Growth Factor Receptor-Targeted Therapies in Breast Cancer
por: Sobhani, Navid, et al.
Publicado: (2018)

Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer
por: Sobhani, Navid, et al.
Publicado: (2019)

An update on antibody–drug conjugates in urothelial carcinoma: state of the art strategies and what comes next
por: D’Angelo, Alberto, et al.
Publicado: (2022)

CTLA-4 in Regulatory T Cells for Cancer Immunotherapy
por: Sobhani, Navid, et al.
Publicado: (2021)

Tumour infiltrating lymphocytes and immune-related genes as predictors of outcome in pancreatic adenocarcinoma
por: D’Angelo, Alberto, et al.
Publicado: (2019)

Advances in anti-BRAF therapies for lung cancer
por: Roviello, Giandomenico, et al.
Publicado: (2021)

Therapeutic cancer vaccines: From biological mechanisms and engineering to ongoing clinical trials
por: Sobhani, Navid, et al.
Publicado: (2022)

The Role of Genomics and Proteomics in Lung Cancer Early Detection and Treatment †
por: Abbasian, Mohammad Hadi, et al.
Publicado: (2022)

Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted Therapies
por: D’Angelo, Alberto, et al.
Publicado: (2020)

MSI and EBV Positive Gastric Cancer’s Subgroups and Their Link with Novel Immunotherapy
por: Rodriquenz, Maria Grazia, et al.
Publicado: (2020)

Circulating tumor cells correlate with patterns of recurrence in patients with hormone-sensitive prostate cancer
por: Roviello, Giandomenico, et al.
Publicado: (2017)

Comparison of DNA vaccines with AS03 as an adjuvant and an mRNA vaccine against SARS-CoV-2
por: Neeli, Praveen, et al.
Publicado: (2023)

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer
por: Roviello, Giandomenico, et al.
Publicado: (2020)

Immune Checkpoint Inhibitors in Pre-Treated Gastric Cancer Patients: Results from a Literature-Based Meta-Analysis
por: Roviello, Giandomenico, et al.
Publicado: (2020)

Targeting the androgenic pathway in elderly patients with castration-resistant prostate cancer: A meta-analysis of randomized trials
por: Roviello, Giandomenico, et al.
Publicado: (2016)

Second line of treatment for HER2-positive gastric cancer: an evolving issue
por: Roviello, Giandomenico, et al.
Publicado: (2021)

C1QBP regulates mitochondrial plasticity to impact tumor progression and antitumor immune response
por: Wang, Qiping, et al.
Publicado: (2022)

Cyclin dependent kinase 4 and 6 inhibitors as novel therapeutic agents for targeted treatment of malignant mesothelioma
por: Sobhani, Navid, et al.
Publicado: (2017)

Clinico-Immunological Effects of a Single-Agent CDK4/6 Inhibitor in Advanced HR+/HER2− Breast Cancer Based on a Window of Opportunity Study
por: D’Angelo, Alberto, et al.
Publicado: (2022)

Isolated Testicular Metastasis from Prostate Cancer
por: Bonetta, Alberto, et al.
Publicado: (2017)

Enteric-coated and highly standardized cranberry extract reduces antibiotic and nonsteroidal anti-inflammatory drug use for urinary tract infections during radiotherapy for prostate carcinoma
por: Bonetta, Alberto, et al.
Publicado: (2017)

Current status of PI3K-mTOR inhibition in hormone-receptor positive, HER2-negative breast cancer
por: Sobhani, Navid, et al.
Publicado: (2018)

Circulating cell-free nucleic acids as prognostic and therapy predictive tools for metastatic castrate-resistant prostate cancer
por: Sobhani, Navid, et al.
Publicado: (2020)

Targeting Aberrant FGFR Signaling to Overcome CDK4/6 Inhibitor Resistance in Breast Cancer
por: Sobhani, Navid, et al.
Publicado: (2021)

DNA repair deficiency as circulating biomarker in prostate cancer
por: Catalano, Martina, et al.
Publicado: (2023)

Distribution of KRAS, DDR2, and TP53 gene mutations in lung cancer: An analysis of Iranian patients
por: Fathi, Zahra, et al.
Publicado: (2018)

The Fibroblast Growth Factor Receptors in Breast Cancer: from Oncogenesis to Better Treatments
por: Sobhani, Navid, et al.
Publicado: (2020)

HMGB1/GPC3 dual targeting vaccine induces dendritic cells-mediated CD8(+)T cell immune response and elicits potential therapeutic effect in hepatocellular carcinoma
por: Shi, Xiaoqing, et al.
Publicado: (2023)

Methylene Blue—Current Knowledge, Fluorescent Properties, and Its Future Use
por: Cwalinski, Tomasz, et al.
Publicado: (2020)

AI-powered discovery of a novel p53-Y220C reactivator
por: Zhou, Shan, et al.
Publicado: (2023)

CD44 and CD24 cannot act as cancer stem cell markers in human lung adenocarcinoma cell line A549
por: Roudi, Raheleh, et al.
Publicado: (2013)

Hypoxia-related biological markers as predictors of epirubicin-based treatment responsiveness and resistance in locally advanced breast cancer
por: Milani, Manuela, et al.
Publicado: (2017)

The co-delivery of adenovirus-based immune checkpoint vaccine elicits a potent anti-tumor effect in renal carcinoma
por: Jiang, Nan, et al.
Publicado: (2023)

Analysis of PD-L1 and CD3 Expression in Glioblastoma Patients and Correlation with Outcome: A Single Center Report
por: Sobhani, Navid, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_kmho06pdchs9hkr4kb9ndp5j4k